SSY Group (HK:2005) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SSY Group Limited has announced that their Nefopam Hydrochloride Injection, a treatment for acute pain such as postoperative discomfort, has become the first generic drug to pass the Consistency Evaluation of Quality and Efficacy by China’s National Medical Products Administration. This milestone is part of the company’s recent product development updates intended to inform shareholders and potential investors about the company’s progress.
For further insights into HK:2005 stock, check out TipRanks’ Stock Analysis page.